Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer: (Rapamycin Inhibition of DDSP [RID])

NCT02565901 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02565901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02565901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer: (Rapamycin Inhibition of DDSP [RID])
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Terminated
Start date
February 29, 2016
Completion date
June 16, 2020
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic malignant neoplasm in the bone, metastatic prostate carcinoma, stage iv prostate cancer ajcc v7